IN2015DN01736A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN01736A IN2015DN01736A IN1736DEN2015A IN2015DN01736A IN 2015DN01736 A IN2015DN01736 A IN 2015DN01736A IN 1736DEN2015 A IN1736DEN2015 A IN 1736DEN2015A IN 2015DN01736 A IN2015DN01736 A IN 2015DN01736A
- Authority
- IN
- India
- Prior art keywords
- ccr1
- compounds
- antagonists
- assays
- act
- Prior art date
Links
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 abstract 2
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000004500 CCR1 Receptors Human genes 0.000 abstract 1
- 108010017319 CCR1 Receptors Proteins 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- -1 aryl piperazine derivatives Chemical class 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000002860 competitive effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
- A61L2300/436—Inhibitors, antagonists of receptors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compounds are provided that act as potent antagonists of the CCR1 receptor and have in vivo anti inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions methods for the treatment of CCR1 mediated diseases and as controls in assays for the identification of competitive CCR1 antagonists.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261693758P | 2012-08-27 | 2012-08-27 | |
| US201361831694P | 2013-06-06 | 2013-06-06 | |
| PCT/US2013/056796 WO2014035967A2 (en) | 2012-08-27 | 2013-08-27 | Antagonists of chemokine receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN01736A true IN2015DN01736A (en) | 2015-05-29 |
Family
ID=50148523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1736DEN2015 IN2015DN01736A (en) | 2012-08-27 | 2013-08-27 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9181241B2 (en) |
| EP (1) | EP2888261B1 (en) |
| JP (1) | JP6339573B2 (en) |
| KR (1) | KR102103188B1 (en) |
| CN (1) | CN104955454B (en) |
| AU (1) | AU2013308988B2 (en) |
| BR (1) | BR112015004254A2 (en) |
| CA (1) | CA2883353C (en) |
| DK (1) | DK2888261T3 (en) |
| ES (1) | ES2681499T3 (en) |
| HK (1) | HK1211588A1 (en) |
| IL (1) | IL237477B (en) |
| IN (1) | IN2015DN01736A (en) |
| MX (1) | MX367436B (en) |
| PT (1) | PT2888261T (en) |
| RU (1) | RU2646762C2 (en) |
| SG (1) | SG11201501479QA (en) |
| WO (1) | WO2014035967A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019510832A (en) * | 2016-04-07 | 2019-04-18 | ケモセントリクス，インコーポレーテッド | Reduction of tumor burden by administering a CCR1 antagonist in combination with a PD-1 inhibitor or PD-L1 inhibitor |
| CN106986878A (en) * | 2017-03-31 | 2017-07-28 | 牡丹江医学院 | A kind of medicine for preventing and treating nettle rash and preparation method thereof |
| CN111269192A (en) * | 2020-02-25 | 2020-06-12 | 成都睿智化学研究有限公司 | Synthesis method of 5-hydroxymethyl tetrazole and derivatives thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050256130A1 (en) * | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
| US7589199B2 (en) | 2002-06-12 | 2009-09-15 | Chemocentryx, Inc. | Substituted piperazines |
| US7576106B2 (en) * | 2005-10-11 | 2009-08-18 | Chemocentryx, Inc. | Piperidine derivatives and methods of use |
| EA015529B1 (en) * | 2007-05-22 | 2011-08-30 | Кемосентрикс, Инк. | 3-(imidazolyl)pyrazolo[3,4-b]pyridines |
| EP2655371B1 (en) * | 2010-12-23 | 2015-02-25 | Boehringer Ingelheim International GmbH | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
-
2013
- 2013-08-27 EP EP13833111.1A patent/EP2888261B1/en active Active
- 2013-08-27 PT PT138331111T patent/PT2888261T/en unknown
- 2013-08-27 IN IN1736DEN2015 patent/IN2015DN01736A/en unknown
- 2013-08-27 RU RU2015110982A patent/RU2646762C2/en not_active IP Right Cessation
- 2013-08-27 WO PCT/US2013/056796 patent/WO2014035967A2/en active Application Filing
- 2013-08-27 CN CN201380053289.7A patent/CN104955454B/en active Active
- 2013-08-27 ES ES13833111.1T patent/ES2681499T3/en active Active
- 2013-08-27 DK DK13833111.1T patent/DK2888261T3/en active
- 2013-08-27 CA CA2883353A patent/CA2883353C/en active Active
- 2013-08-27 AU AU2013308988A patent/AU2013308988B2/en active Active
- 2013-08-27 US US14/011,174 patent/US9181241B2/en active Active
- 2013-08-27 MX MX2015002514A patent/MX367436B/en active IP Right Grant
- 2013-08-27 KR KR1020157008002A patent/KR102103188B1/en active IP Right Grant
- 2013-08-27 SG SG11201501479QA patent/SG11201501479QA/en unknown
- 2013-08-27 BR BR112015004254A patent/BR112015004254A2/en not_active IP Right Cessation
- 2013-08-27 JP JP2015529926A patent/JP6339573B2/en active Active
-
2015
- 2015-02-26 IL IL237477A patent/IL237477B/en active IP Right Grant
- 2015-10-08 US US14/878,818 patent/US20160193191A1/en not_active Abandoned
- 2015-12-18 HK HK15112516.3A patent/HK1211588A1/en unknown
-
2018
- 2018-02-20 US US15/900,405 patent/US20180369213A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6339573B2 (en) | 2018-06-06 |
| EP2888261A2 (en) | 2015-07-01 |
| RU2646762C2 (en) | 2018-03-07 |
| US9181241B2 (en) | 2015-11-10 |
| AU2013308988A1 (en) | 2015-03-12 |
| CA2883353A1 (en) | 2014-03-06 |
| HK1211588A1 (en) | 2016-05-27 |
| MX2015002514A (en) | 2015-10-12 |
| JP2015530386A (en) | 2015-10-15 |
| KR102103188B1 (en) | 2020-04-23 |
| KR20150058264A (en) | 2015-05-28 |
| CN104955454A (en) | 2015-09-30 |
| WO2014035967A2 (en) | 2014-03-06 |
| AU2013308988B2 (en) | 2017-09-28 |
| EP2888261A4 (en) | 2016-04-27 |
| IL237477B (en) | 2020-07-30 |
| MX367436B (en) | 2019-08-21 |
| IL237477A0 (en) | 2015-04-30 |
| WO2014035967A3 (en) | 2015-07-16 |
| US20180369213A1 (en) | 2018-12-27 |
| US20140057937A1 (en) | 2014-02-27 |
| PT2888261T (en) | 2018-07-25 |
| CN104955454B (en) | 2018-06-29 |
| CA2883353C (en) | 2020-09-15 |
| US20160193191A1 (en) | 2016-07-07 |
| BR112015004254A2 (en) | 2017-07-04 |
| SG11201501479QA (en) | 2015-04-29 |
| RU2015110982A (en) | 2016-10-20 |
| ES2681499T3 (en) | 2018-09-13 |
| EP2888261B1 (en) | 2018-04-18 |
| DK2888261T3 (en) | 2018-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL257581A (en) | Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| PH12015501289B1 (en) | Novel benzimidazole derivatives as ep4 antagonists | |
| IL236221A (en) | Thienopyridone derivatives and pharmaceutical compositions comprising them for the treatment of diseases | |
| MX2016011632A (en) | Azaspiro derivatives as trpm8 antagonists. | |
| IN2014CN03597A (en) | ||
| MY193728A (en) | Muscarinic receptor agonists | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| EP2155203A4 (en) | Azaindazole compounds and methods of use | |
| MY172308A (en) | Bicyclic pyrazinone derivatives | |
| MX2015007051A (en) | Diazole lactams. | |
| WO2014070991A3 (en) | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists | |
| IN2014KN02906A (en) | ||
| MX2015007853A (en) | Diazole amides. | |
| IL268757A (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| IN2015DN01736A (en) | ||
| MX2015005312A (en) | 1 h-indole-3-carboxamide derivatives and use thereof as p2y12 antagonists. | |
| WO2016083315A8 (en) | Use of ox1r antagonists for the treatment of inflammatory bowel diseases | |
| MX2017008497A (en) | Novel heterocyclic compounds and the use thereof in medicine and in cosmetics. |